Protocol No.: M24-287

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL
Principal Investigator
Veltri, Lauren
Phase
III
Age Group
Adult
Applicable Disease Site
Leukemia
Participating Institutions
Mary Babb Randolph Cancer Center
West Virginia University
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov